Non-alcoholic fatty liver disease in children

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 3, 2012, Pages 297-300

  Janczyk, Wojciech ^a   Socha, Piotr ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCYSTEINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA TOCOPHEROL; AMINOTRANSFERASE; AMIODARONE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; CARNITINE; ESTROGEN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; METHOTREXATE; NIFEDIPINE; PIOGLITAZONE; PREDNISOLONE; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RETINOL; TAMOXIFEN; TRIACYLGLYCEROL; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

AEROBIC EXERCISE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG MEGADOSE; DYSLIPIDEMIA; ECHOGRAPHY; EPIDEMIOLOGICAL DATA; FAMILIAL DISEASE; FATTY LIVER; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

BIOPSY; CHILD; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; LIVER; METFORMIN; OBESITY; THIAZOLIDINEDIONES; TRANSAMINASES; WEIGHT LOSS;

EID: 84861732714     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.03.026     Document Type: Article

References (6)

1. Vajro P, Lenta S, Socha P, Dhawan A, Nobili V, McKiernan P, et al. Diagnosis of Non-alcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. JPGN (up-to-date ESPGHAN consensus on diagnosis of NAFLD). doi:10.1097/MPG.0b013e318252a13f.
2. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. (point of reference in histological scoring in NAFLD).
3. Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011, 15(6):CD003619. (comprehensive systematic review of literature on weight reduction methods in NAFLD).
4. Socha P., Horvath A., Vajro P., et al. Systematic review: pharmacological interventions for non-alcoholic fatty liver disease in adults and in children. J Pediatr Gastroenterol Nutr 2009, 48:587-596. (recent systematic review of pharmacological treatment in NAFLD).
5. Musso G., Gambino R., Cassader M., et al. A meta-analysis of randomized trials for the treatment of non-alcoholic fatty liver disease. Hepatology 2010, 52:79-104. (most recent meta-analysis of pharmacological treatment in NAFLD).
6. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of non-alcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668. (recent large study comparing the efficacy of pharmacological agents in children with NAFLD).